期刊文献+

中国乳腺癌高风险人群中TP53基因胚系突变的研究 被引量:5

Germline mutations of TP53 gene among Chinese families with high risk for breast cancer
原文传递
导出
摘要 目的研究中国乳腺癌高风险人群中TP53基因胚系突变的情况。方法应用目标区域捕获和大规模平行测序的方法,对81个来自肿瘤高风险家系、BRCA1/2突变阴性的乳腺癌先证者基因组DNA进行TP53基因的突变检测。挑选候选突变进行Sanger测序验证及共分离研究。结果在81例BRCA1/2突变阴性的乳腺癌先证者中,分别在3例乳腺癌先证者中发现3个位于TP53外显子区的突变。其中两个为已知突变,一个为新发现的突变。1例TP53突变携带者的家族史符合Li—Fraumeni综合征的标准,占所有符合Li—Fraumeni综合征标准家系的9.1%(1/11)。2例TP53突变携带者诊断乳腺癌时的年龄小于30岁,占所有非常年轻乳腺癌患者(≤30岁)的11.8%(2/17)。结论TP53在中国乳腺癌高风险人群中有较高的检出率,提示在这一高危人群中,尤其是家族史符合Li—Fraumeni综合征标准的患者或BRCA1/2基因突变阴性的非常年轻乳腺癌患者应该接受TP53突变的检测。 Objective To evaluate the role of germline mutations of TP53 gene among a Chinese population with high risk for breast cancer. Methods A total of 81 BRCA-negative breast cancer probands from cancer families were analyzed using targeted capture and next-generation sequencing. Candidate mutations were verified with Sanger sequencing. Co-segregation analyses were carried out to explore the likely pathogenicity of the mutation. Results Of the 81 BRCA-negative patients, 3 exonic mutations in the TP53 gene were identified in 3 breast cancer patients. Of these, 2 mutations were previously reported and 1 was novel. One family with TP53 mutation has met the criteria for Li-Fraumeni syndrome (LFS) and accounted for 9.1% of all families who fulfilled the diagnostic criteria for LFS. Two of the carriers were diagnosed with breast cancer under the age of 30, and have accounted for 11.8% (2/17) of all very young (430 years) breast cancer patients in our study. Conclusion The TP53 germline mutation is more common in Chinese population with a high risk for breast cancer than previously thought. TP53 gene mutation screening should be considered particularly for patients with a family history of LFS and very young age of onset.
出处 《中华医学遗传学杂志》 CAS CSCD 北大核心 2015年第6期761-765,共5页 Chinese Journal of Medical Genetics
基金 上海市科委科技支撑项目(14441901402)
关键词 乳腺癌 TP53基因 胚系突变 Breast cancer TP53 gene Germline mutation
  • 相关文献

参考文献27

  • 1Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome o[ breast cancer, sarcomas, and otherneoplasms[J]. Science, 1990,250(4985) ..1233-1238.
  • 2Birch JM, Hartley AL, Tricker KJ, et al, Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumenifamilies [J]. Cancer Rest 1994,54(5) :1298-1304.
  • 3Prosser J, Elder PA, Condie A, et al. Mutations in p53 do not account for heritable breast cancer: a study in five affected families l-J]. Br J Cancer, 1991,63(2) :181-184.
  • 4Mouchawar J, Korch C, Byers T, et al. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study[J]. Cancer Res, 2010,70(12) :4795-4800.
  • 5Lalloo F, Varley J, Moran A, et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives [J]. Eur J Cancer, 2006,42(8) :1143-1150.
  • 6Lee DS, Yoon SY, Looi LM, et al. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCAI/2 screening to early-onset breast cancer patients [J]. Breast Cancer Res, 2012,14(2) :R66.
  • 7Yang XC, Wu J, Lu JS, et al. Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing [J]. PIoS One, 2015,10 : e0125571.
  • 8Li FP, Fraumeni JJ, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds [J]. Cancer Res, 1988, 48 (18) : 5358-5362.
  • 9Chompret A, Abel A, Stoppa-Lyonnet D, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening [J]. J Med Genet, 2001,38(1) :43-47.
  • 10Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome [J]. J Clin Oncol, 2009,27(26):e108-e109, ell0.

二级参考文献12

  • 1Michalkiewicz E, Sandrin R, Figueiredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the Intemational Pediatric Adrenocortical Tumor Registry. J Clin Oncol, 2004, 22:838-845.
  • 2West AN, Neale GA, Pounds S, et al. Gene expression profiling of childhood adrenocortical tumors. Cancer Res, 2007, 67: 600-608.
  • 3Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat, 2003, 21:313-320.
  • 4Rosati R, Cerrato F, Doghman M, et al. High frequency of loss of heterozygosity at 11 p15 and IGF2 overexpression are not related to clinical outcome in childhood adrenocortical tumors positive for the R337H TP53 mutation. Cancer Genet Cytogenet, 2008, 186: 19-24.
  • 5Varley JM, McGown G, Thorncmft M, et al. Are there lowpenetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet, 1999, 65:995-1006.
  • 6Figueiredo BC, Stratakis CA, Sandrini R, et al. Comparative genomic hybridization analysis of adrenocortical tumors of childhood. J Clin Endocr Metab, 1999, 84:1116-1121.
  • 7Longui CA, Lemos-Marini SH, Figueiredo B, et al.Inhibin alpha-subunit (INHA) gene and locus changes in paediatric adrenocortical tumours from TP53 R337H mutation heterozygote carriers. J Med Genet, 2004, 41:354-359.
  • 8Figueiredo BC, Sandrini R, Zambetti GP, et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet, 2006, 43:91-96.
  • 9Russell-Swetek A, West AN, Mintem JE, et al. Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma. J Med Genet, 2008, 45:603-606.
  • 10Joerger AC, Fersht AR. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene, 2007, 26: 2226-2242.

共引文献1

同被引文献15

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部